Cargando…

Globotriaosylsphingosine Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease

BACKGROUND: Fabry disease (FD) is caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (GLA) resulting in the accumulation of globotriaosylsphingosine (Gb3) in a variety of tissues. While GLA deficiency was always considered as the fulcrum of the disease, recent attention shifted tow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Namdar, Mehdi, Gebhard, Catherine, Studiger, Rafael, Shi, Yi, Mocharla, Pavani, Schmied, Christian, Brugada, Pedro, Lüscher, Thomas F., Camici, Giovanni G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340376/ https://www.ncbi.nlm.nih.gov/pubmed/22558451 http://dx.doi.org/10.1371/journal.pone.0036373

Ejemplares similares

Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease
por: Tsukimura, Takahiro, et al.
Publicado: (2014)

Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
por: Tsukimura, Takahiro, et al.
Publicado: (2021)

Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease
por: Taguchi, Atsumi, et al.
Publicado: (2023)

Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

Plasma Globotriaosylsphingosine and α-Galactosidase A Activity as a Combined Screening Biomarker for Fabry Disease in a Large Japanese Cohort
por: Maruyama, Hiroki, et al.
Publicado: (2021)

Monitoring globotriaosylsphingosine in a Korean male patient with Fabry disease
por: Jang, Heejoon, et al.
Publicado: (2019)

Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease
por: Ouyang, Yan, et al.
Publicado: (2018)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease
por: Hofmann, Lukas, et al.
Publicado: (2017)

Adipocytes participate in storage in α-galactosidase deficiency (Fabry disease)
por: Hůlková, Helena, et al.
Publicado: (2010)

Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy
por: Franzen, Daniel, et al.
Publicado: (2018)

A new mutation found in newborn screening for Fabry disease evaluated by plasma globotriaosylsphingosine levels
por: Chinen, Yasutsugu, et al.
Publicado: (2017)

Lyso-globotriaosylsphingosine induces endothelial dysfunction via autophagy-dependent regulation of necroptosis
por: Hwang, Ae-Rang, et al.
Publicado: (2023)

A Novel Frameshift Mutation of Galactosidase-alpha in Fabry Disease Restricted to Dermatologic Manifestations
por: Kim, Dae Hun, et al.
Publicado: (2013)

Rats deficient in α-galactosidase A develop ocular manifestations of Fabry disease
por: Miller, James J., et al.
Publicado: (2019)

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
por: Lenders, Malte, et al.
Publicado: (2016)

Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease
por: Monticelli, Maria, et al.
Publicado: (2023)

Optimizing human α-galactosidase for treatment of Fabry disease
por: Hallows, William C., et al.
Publicado: (2023)

Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones
por: Monticelli, Maria, et al.
Publicado: (2022)

Analysis of Lyso-Globotriaosylsphingosine in Dried Blood Spots
por: Johnson, Britt, et al.
Publicado: (2013)

Electrocardiographic Changes and Arrhythmia in Fabry Disease
por: Namdar, Mehdi
Publicado: (2016)

Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development
por: Üçeyler, Nurcan, et al.
Publicado: (2016)

Functional Characterisation of Alpha-Galactosidase A Mutations as a Basis for a New Classification System in Fabry Disease
por: Lukas, Jan, et al.
Publicado: (2013)

Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease
por: Citro, Valentina, et al.
Publicado: (2016)

Human Alpha Galactosidases Transiently Produced in Nicotiana benthamiana Leaves: New Insights in Substrate Specificities with Relevance for Fabry Disease
por: Kytidou, Kassiani, et al.
Publicado: (2017)

Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease
por: van der Veen, Sanne J., et al.
Publicado: (2020)

α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes
por: Jehn, Ulrich, et al.
Publicado: (2021)

Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice
por: Shen, Jin-Song, et al.
Publicado: (2015)

Receptor-Mediated Endocytosis of α-Galactosidase A in Human Podocytes in Fabry Disease
por: Prabakaran, Thaneas, et al.
Publicado: (2011)

A Novel α-Galactosidase A Splicing Mutation Predisposes to Fabry Disease
por: Li, Ping, et al.
Publicado: (2019)

Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase A after 6 years of enzyme replacement therapy
por: Hongo, Kenichi, et al.
Publicado: (2020)

Mass Spectrometry Analysis of Globotriaosylsphingosine and Its Analogues in Dried Blood Spots
por: Boutin, Michel, et al.
Publicado: (2023)

Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles
por: Oder, Daniel, et al.
Publicado: (2016)

High Throughput Screening for Inhibitors of Alpha-Galactosidase
por: Motabar, Omid, et al.
Publicado: (2010)

Bioconversion of Beet Molasses to Alpha-Galactosidase and Ethanol
por: Álvarez-Cao, María-Efigenia, et al.
Publicado: (2019)

Epithelial–Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide
por: Jeon, Yeo Jin, et al.
Publicado: (2015)

Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease
por: Modrego, Andrea, et al.
Publicado: (2021)

α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice
por: Rodríguez-Castejón, Julen, et al.
Publicado: (2021)

Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome
por: Rombach, Saskia M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_h6at7ar0q0o9dj01afv15r5bk5